Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial

The Lancet Infectious Diseases

Volumn 17, Issue 10, 2017, Pages 1062-1068

  Forns, Xavier ^a   Lee, Samuel S ^b   Valdes, Joaquin ^c   Lens, Sabela ^a   Ghalib, Reem ^d   Aguilar, Humberto ^e   Felizarta, Franco ^f   Hassanein, Tarek ^g   Hinrichsen, Holger ^h   Rincon, Diego ⁱ   Morillas, Rosa ^j   Zeuzem, Stefan ^k   Horsmans, Yves ^l   Nelson, David R ^m   Yu, Yao ^c   Krishnan, Preethi ^c   Lin, Chih Wei ^c   Kort, Jens J ^c   Mensa, Federico J ^c  

^a UNIVERSITY OF BARCELONA   (Spain)

^b UNIVERSITY OF CALGARY   (Canada)

^c ABBVIE INC   (United States)

^d Texas Digestive Disease Consultants   (United States)

^e Louisiana Blood Center   (United States)

^f Private Practice   (United States)

^g Southern California Liver Centers and Southern California Research Center   (United States)

^h UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

ⁱ HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^j HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^k GOETHE UNIVERSITY   (Germany)

^l CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^m UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; GLECAPREVIR; HEMOGLOBIN; PEGINTERFERON; PIBRENTASVIR; RIBAVIRIN; SOFOSBUVIR; ABT-493; ANTIVIRUS AGENT; BENZIMIDAZOLE DERIVATIVE; QUINOXALINE DERIVATIVE; SULFONAMIDE;

ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; BELGIUM; CANADA; CAUSE OF DEATH; CHILD PUGH SCORE; CHRONIC HEPATITIS C; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; ESOPHAGUS VARICES; FATIGUE; FEMALE; GERMANY; HEADACHE; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 2; HEPATITIS C VIRUS GENOTYPE 4; HEPATITIS C VIRUS GENOTYPE 5; HEPATITIS C VIRUS GENOTYPE 6; HISPANIC; HUMAN; INTENTION TO TREAT ANALYSIS; INTERNATIONAL NORMALIZED RATIO; LIMIT OF QUANTITATION; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NEUTROPHIL COUNT; OPEN STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; SOUTH AFRICA; SPAIN; SUSTAINED VIROLOGIC RESPONSE; THROMBOCYTE COUNT; UNITED STATES; URINARY TRACT INFECTION; CLASSIFICATION; CLINICAL TRIAL; COMBINATION DRUG THERAPY; COMPLICATION; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C; MIDDLE AGED; VERY ELDERLY; VIROLOGY;

ADULT; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; BENZIMIDAZOLES; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; QUINOXALINES; SULFONAMIDES;

EID: 85027407746     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(17)30496-6     Document Type: Article

References (31)

1. Mohd Hanafiah, K, Groeger, J, Flaxman, AD, Wiersma, ST, Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 57 (2013), 1333–1342.
2. Messina, JP, Humphreys, I, Flaxman, A, et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology 61 (2015), 77–87.
3. Blach S, Estes C, Gamkrelidze I, et al. Polaris Observatory—global prevelance of hepatitis C. American Association for the Study of Liver Diseases: The Liver Meeting; Boston, MA, USA; Nov 11–15, 2016. 753 (abstr).
4. Davis, GL, Alter, MJ, El-Serag, H, Poynard, T, Jennings, LW, Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 138 (2010), 513–521.
5. Fattovich, G, Giustina, G, Degos, F, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 112 (1997), 463–472.
6. Webster, DP, Klenerman, P, Dusheiko, GM, Hepatitis C. Lancet 385 (2015), 1124–1135.
7. WHO. Hepatitis C fact sheet. http://www.who.int/mediacentre/factsheets/fs164/en/, April, 2017 (accessed Feb 2, 2017).
8. Smith, DB, Bukh, J, Kuiken, C, et al. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology 59 (2014), 318–327.
9. Gower, E, Estes, C, Blach, S, Razavi-Shearer, K, Razavi, H, Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 61:suppl 1 (2014), S45–S57.
10. Asselah, T, Boyer, N, Saadoun, D, Martinot-Peignoux, M, Marcellin, P, Direct-acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN-free treatment and future perspectives. Liver Int 36:suppl 1 (2016), 47–57.
11. Panel, AIHG, Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology 62 (2015), 932–954.
12. European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2016. J Hepatol 66 (2017), 153–194.
13. Schinazi, RF, Asselah, T, From HCV to HBV cure. Liver Int 37:suppl 1 (2017), 73–80.
14. Ng, TI, Krishnan, P, Pilot-Matias, T, et al. In vitro antiviral activity and resistance profile of the next generation hepatitis C virus NS5A inhibitor pibrentasvir. Antimicrob Agents Chemother 61 (2017), e02558–e02561.
15. Ng T, Reisch T, Middleton T, et al. ABT-493, a potent HCV NS3/4A protease inhibitor with broad genotypic coverage. 21st Annual Conference on Retroviruses and Opportunistic Infections; Boston, MA, USA; March 3–6, 2014. 636 (abstr).
16. Gane, E, Poordad, F, Wang, S, et al. High efficacy of ABT-493 and ABT-530 treatment in patients with HCV genotype 1 or 3 infection and compensated cirrhosis. Gastroenterology, 151, 2016, 651 59.e1.
17. Wyles D, Poordad F, Wang S, et al. SURVEYOR-II, part 3: efficacy and safety of glecaprevir/pibrentasvir in patients with hepatits C virus genotype 3 infection with prior treatment experience and/or cirrhosis. American Association for the Study of Liver Diseases: The Liver Meeting; Boston, MA, USA; Nov 11–15, 2016. 113 (abstr).
18. Gilead Sciences. Harvoni (sofosbuvir and ledipasvir) [package insert]. https://www.gilead.com/∼/media/Files/pdfs/medicines/liver-disease/harvoni/harvoni_pi.pdf, 2014 (accessed April 20, 2017).
19. Sovaldi (sofosbuvir tablet) [package insert], 2015, Gilead Sciences, Foster City, CA.
20. Zeuzem, S, Ghalib, R, Reddy, KR, et al. Grazoprevir-elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic HCV genotype 1, 4, or 6 infection: a randomized trial. Ann Intern Med 163 (2015), 1–13.
21. Feld, JJ, Jacobson, IM, Hezode, C, et al. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med 373 (2015), 2599–2607.
22. Foster, GR, Afdhal, N, Roberts, SK, et al. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med 373 (2015), 2608–2617.
23. Gane E, Lawitz E, Pugatch D. EXPEDITION-4: efficacy and safety of glecaprevir/pibrentasvir in patients with renal impairment and chronic hepatitis C virus genoypes 1-6 infection. American Association for the Study of Liver Diseases: The Liver Meeting; Boston, MA, USA; Nov 11–15, 2016. LB-11 (abstr).
24. Reddy, KR, Bourliere, M, Sulkowski, M, et al. Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: an integrated safety and efficacy analysis. Hepatology 62 (2015), 79–86.
25. Jacobson, IM, Lawitz, E, Kwo, PY, et al. Safety and efficacy of elbasvir/grazoprevir in patients with hepatitis C virus infection and compensated cirrhosis: an integrated analysis. Gastroenterology, 152, 2017, 1372 82.e2.
26. Gilead Sciences. Epclusa (sofosbuvir and velpatasvir) [package insert]. http://www.gilead.com/∼/media/Files/pdfs/medicines/liver-disease/epclusa/epclusa_pi.pdf, 2016 (accessed April 20, 2017).
27. Asselah T, Hazode C, Zadeikis N, et al. ENDURANCE-4: efficacy and safety of glecaprevir/pibrentasvir (formerly ABT-493/ABT-530) treatment in patients with chronic HCV genotype 4, 5, or 6 infection. American Association for the Study of Liver Diseases: international conference: The Liver Meeting; Boston, MA, USA; Nov 11–15, 2016. 114 (abstr).
28. Kowdley KV, Colombo M, Zadeikis N, et al. ENDURANCE-2: safety and efficacy of glecaprevir/pibrentasvir in hepatitis C virus genotype 2-infected patients without cirrhosis: a randomized, double-blind, placebo-controlled study. American Association for the Study of Liver Diseases: international conference: The Liver Meeting; Boston, MA, USA; Nov 11–15, 2016. 73 (abstr).
29. Hassanein T, Wyles D, Wang S, et al. Glecaprevir/pibrentasvir demonstrates high SVR rates in patients with HCV genotype 2, 4, 5, or 6 infection without cirrhosis following an 8-week treatment duration: SURVEYOR-II, Part 4). American Association for the Study of Liver Diseases: international conference; Boston, MA, USA; Nov 11–15, 2016. LB-15 (abstr).
30. Zeuzem S, Feld J, Wang S, et al. ENDURANCE-1: efficacy and safety of 8- versus 12-week treatment with ABT-493/ABT-530 in patients with chronic HCV genotype 1 infection. American Association for the Study of Liver Diseases: The Liver Meeting; Boston, MA, USA; Nov 11–15, 2016. 253 (abstr).
31. Rockstroh J, Lacombe K, Viani RM, et al. Efficacy and safety of glecaprevir/pibrentasvir in patients co-infected with hepatitis C virus and human immunodeficiency virus-1: The EXPEDITION-2 Study. International Liver Congress; Amsterdam, Netherlands; April 19–21, 2017. 522 (abstr).